Denise Tami Yamashita1, Chao Li1, Drew Bethune1, Harry Henteleff1, James Ellsmere1. 1. From the Division of General, Surgery, Dalhousie University, Halifax, NS (Yamashita, Li, Ellsmere); and the Division of Thoracic Surgery, Dalhousie University, Halifax, NS (Bethune, Henteleff).
Abstract
BACKGROUND: Endoscopic mucosal resection (EMR) is increasingly being used as a first-line treatment for Barrett esophagus (BE) with high-grade dysplasia (HGD) and intramucosal adenocarcinoma (IMC). We reviewed our experience with endoscopic treatment of BE with HGD and IMC at our institution with respect to eradication rates, complications and long-term recurrence. METHODS: We performed a single-centre retrospective review of all patients referred between October 2010 and August 2014 for EMR with dysplastic BE or IMC. We performed EMR using a cap-fitted endoscope, and the procedure was repeated every 3 months until eradication or progression of disease. RESULTS: A total of 28 patients were identified: 16 with dysplastic BE (14 HGD, 1 low-grade dysplasia, 1 intermediate dysplasia) and 12 with IMC. Complete eradication of HGD was achieved in 11 of 14 (79%) patients. Three of 12 (25%) patients initially referred with suspected IMC were found to have invasive adenocarcinoma on EMR. Eradication was successful in 8 of 9 (89%) patients with true IMC, with 1 patient progressing to salvage esophagectomy. Complications occurred in 2 of 28 (7%) patients; both had esophageal strictures managed with dilatation. Median duration of follow-up was 371 days. CONCLUSION: Our experience supports the safety of EMR as a first-line treatment for patients with BE with dysplasia and IMC in early short-term follow-up.
BACKGROUND: Endoscopic mucosal resection (EMR) is increasingly being used as a first-line treatment for Barrett esophagus (BE) with high-grade dysplasia (HGD) and intramucosal adenocarcinoma (IMC). We reviewed our experience with endoscopic treatment of BE with HGD and IMC at our institution with respect to eradication rates, complications and long-term recurrence. METHODS: We performed a single-centre retrospective review of all patients referred between October 2010 and August 2014 for EMR with dysplastic BE or IMC. We performed EMR using a cap-fitted endoscope, and the procedure was repeated every 3 months until eradication or progression of disease. RESULTS: A total of 28 patients were identified: 16 with dysplastic BE (14 HGD, 1 low-grade dysplasia, 1 intermediate dysplasia) and 12 with IMC. Complete eradication of HGD was achieved in 11 of 14 (79%) patients. Three of 12 (25%) patients initially referred with suspected IMC were found to have invasive adenocarcinoma on EMR. Eradication was successful in 8 of 9 (89%) patients with true IMC, with 1 patient progressing to salvage esophagectomy. Complications occurred in 2 of 28 (7%) patients; both had esophageal strictures managed with dilatation. Median duration of follow-up was 371 days. CONCLUSION: Our experience supports the safety of EMR as a first-line treatment for patients with BE with dysplasia and IMC in early short-term follow-up.
Authors: Hiran C Fernando; Sudish C Murthy; Wayne Hofstetter; Joseph B Shrager; Charles Bridges; John D Mitchell; Rodney J Landreneau; Ellen R Clough; Thomas J Watson Journal: Ann Thorac Surg Date: 2009-06 Impact factor: 4.330
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: N S Buttar; K K Wang; T J Sebo; D M Riehle; K K Krishnadath; L S Lutzke; M A Anderson; T M Petterson; L J Burgart Journal: Gastroenterology Date: 2001-06 Impact factor: 22.682
Authors: Jennifer Chennat; Vani J A Konda; Andrew S Ross; Alberto Herreros de Tejada; Amy Noffsinger; John Hart; Shang Lin; Mark K Ferguson; Mitchell C Posner; Irving Waxman Journal: Am J Gastroenterol Date: 2009-08-18 Impact factor: 10.864
Authors: Vani J A Konda; Mariano Gonzalez Haba Ruiz; Ann Koons; John Hart; Shu-Yuan Xiao; Uzma D Siddiqui; Mark K Ferguson; Mitchell Posner; Marco G Patti; Irving Waxman Journal: Clin Gastroenterol Hepatol Date: 2014-04-13 Impact factor: 11.382